Eurofins Scientific SE Net Assets
Eurofins Scientific SE net assets. Based on the latest financial reports, Eurofins Scientific SE (ESF0) has net assets worth €4.58 Billion EUR (≈ $5.35 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.99 Billion ≈ $12.84 Billion USD) and total liabilities (€6.41 Billion ≈ $7.49 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Eurofins Scientific SE net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.58 Billion |
| % of Total Assets | 41.66% |
| Annual Growth Rate | 11.23% |
| 5-Year Change | -2.15% |
| 10-Year Change | N/A |
| Growth Volatility | 15.76 |
Net Assets of Eurofins Scientific SE (2016–2025)
Net assets of Eurofins Scientific SE from 2016 to 2025. This chart illustrates how Eurofins Scientific SE's net assets have evolved over time, based on quarterly financial data. See Eurofins Scientific SE (ESF0) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Eurofins Scientific SE (2016–2025)
The table below shows the annual net assets of Eurofins Scientific SE from 2016 to 2025. For live market cap and overall valuation, see ESF0 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.58 Billion ≈ $5.35 Billion |
-15.01% |
| 2024-12-31 | €5.38 Billion ≈ $6.30 Billion |
+4.82% |
| 2023-12-31 | €5.14 Billion ≈ $6.01 Billion |
+5.90% |
| 2022-12-31 | €4.85 Billion ≈ $5.67 Billion |
+3.72% |
| 2021-12-31 | €4.68 Billion ≈ $5.47 Billion |
+25.85% |
| 2020-12-31 | €3.72 Billion ≈ $4.34 Billion |
+28.24% |
| 2019-12-31 | €2.90 Billion ≈ $3.39 Billion |
+6.46% |
| 2018-12-31 | €2.72 Billion ≈ $3.18 Billion |
+9.68% |
| 2017-12-31 | €2.48 Billion ≈ $2.90 Billion |
+41.28% |
| 2016-12-31 | €1.76 Billion ≈ $2.05 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eurofins Scientific SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 952.5% over the analyzed period, indicating profitable operations and earnings retention.
Eurofins Scientific SE Net Assets Breakdown (December 2025)
Eurofins Scientific SE net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €3.02 Billion | 66.55% |
| Other Components | €1.52 Billion | 33.45% |
| Total Equity | €4.54 Billion | 100.00% |
Eurofins Scientific SE Competitors by Market Cap
The table below lists competitors of Eurofins Scientific SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dayforce Inc.
NYSE:DAY
|
$11.18 Billion |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
$11.18 Billion |
|
Power Finance Corporation Limited
NSE:PFC
|
$11.19 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
$11.19 Billion |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
$11.18 Billion |
|
ZTO Express (Cayman) Inc
NYSE:ZTO
|
$11.17 Billion |
|
Deckers Outdoor Corporation
NYSE:DECK
|
$11.17 Billion |
|
Dr. Reddy’s Laboratories Ltd ADR
NYSE:RDY
|
$11.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eurofins Scientific SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,339,000,000 to 4,543,300,000, a change of -795,700,000 (-14.9%).
- Net income of 474,800,000 contributed positively to equity growth.
- Dividend payments of 107,700,000 reduced retained earnings.
- Share repurchases of 541,300,000 reduced equity.
- Other factors decreased equity by 621,500,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €474.80 Million | +10.45% |
| Dividends Paid | €107.70 Million | -2.37% |
| Share Repurchases | €541.30 Million | -11.91% |
| Other Changes | €-621.50 Million | -13.68% |
| Total Change | €- | -14.90% |
Book Value vs Market Value Analysis
This analysis compares Eurofins Scientific SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.27x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €13.85 | €59.14 | x |
| 2018-12-31 | €15.04 | €59.14 | x |
| 2019-12-31 | €15.85 | €59.14 | x |
| 2020-12-31 | €19.34 | €59.14 | x |
| 2021-12-31 | €24.17 | €59.14 | x |
| 2022-12-31 | €24.84 | €59.14 | x |
| 2023-12-31 | €26.42 | €59.14 | x |
| 2024-12-31 | €28.58 | €59.14 | x |
| 2025-12-31 | €25.71 | €59.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eurofins Scientific SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.45%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.51%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 2.42x
- Recent ROE (10.45%) is above the historical average (10.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 10.69% | 6.86% | 0.61x | 2.54x | €11.25 Million |
| 2017 | 8.87% | 7.30% | 0.51x | 2.39x | €-27.55 Million |
| 2018 | 8.39% | 5.92% | 0.52x | 2.70x | €-42.98 Million |
| 2019 | 6.88% | 4.28% | 0.58x | 2.76x | €-88.66 Million |
| 2020 | 14.62% | 9.92% | 0.63x | 2.32x | €170.37 Million |
| 2021 | 16.84% | 11.65% | 0.72x | 2.01x | €317.84 Million |
| 2022 | 12.76% | 9.09% | 0.67x | 2.11x | €131.99 Million |
| 2023 | 6.11% | 4.76% | 0.60x | 2.14x | €-197.55 Million |
| 2024 | 7.61% | 5.85% | 0.64x | 2.04x | €-127.50 Million |
| 2025 | 10.45% | 6.51% | 0.66x | 2.42x | €20.47 Million |
Industry Comparison
This section compares Eurofins Scientific SE's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,132,901,228
- Average return on equity (ROE) among peers: -17.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eurofins Scientific SE (ESF0) | €4.58 Billion | 10.69% | 1.40x | $11.18 Billion |
| IZOTROPIC CORP. (1R3) | $-5.63 Million | 0.00% | 0.00x | $6.44 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $10.41 Million | -90.99% | 0.83x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.06 Billion | 1.68% | 0.19x | $610.33 Million |
| Check-Cap Ltd (7CC) | $-1.45 Million | 0.00% | 0.00x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.50 Billion | 30.79% | 1.04x | $246.03 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $72.09 Million | -40.23% | 0.16x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $13.72 Million | -30.19% | 0.11x | $5.28 Million |
| INOVIQ LTD. (EGQ0) | $19.99 Million | -32.79% | 0.09x | $12.59 Million |
| ICON Public Limited Company (IJF) | $9.52 Billion | 8.31% | 0.77x | $7.52 Billion |
About Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection,… Read more